Ulsan, South Korea
Ulsan, South Korea

The University of Ulsan was founded on February 19, 1969 as the Ulsan Institute of Technology. The University was promoted to a full-fledged University on March 1, 1985. The university is located in Mugeo-dong, Ulsan, South Korea. The University currently has approximately 10,500 students enrolled.The city of Ulsan has been recognized as the Korean city which was built around the corporate base of the multinational Hyundai conglomerate. Thus, the Hyundai Conglomerate announced its plan to give 40 billion won to assist a variety of university-industry cooperation projects.This corporate relationship has helped turn the University into one of South Korea's top rated institutions for graduate job placement, as well as increasing its reputation more broadly as one of the top private universities outside of Seoul. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
University of Ulsan | Date: 2017-07-26

Provided is a floating wind power generation device comprising: a main buoyant body which has buoyancy, so as to float on the sea, and has a space portion provided in the center; an auxiliary buoyant body which has buoyancy and is connected to the main buoyancy and is connected to the main buoyant body by being inserted into the space portion of the main buoyant body; a plurality of wind power generators which are vertically provided on top of the auxiliary buoyant body and generate power; a location control means which is connected to the main buoyant body and controls the location of the main buoyant body; an oscillation inhibiting means which is connected to the main buoyant body and enables the main buoyant body to maintain an equilibrium state by absorbing the sea waves; and a dock connection unit which is connected to the main buoyant body and enables a ship to lie at anchor on the sea. A floating wind power generation device, having a plurality of wind power generators provided on top of an auxiliary buoyant body that is placed in a space portion of a main buoyant body, enables absorbing of the sea waves by means of vertical reciprocating motion energy, generated by means of an oscillation inhibiting means as well as a location control means, so as to prevent the main buoyant body from being affected by the waves and shaking and such that an equilibrium state of the main buoyant body can be maintained, thereby enabling stable wind power generation.


Patent
Korea Institute of Science, Technology, The Asan Foundation and University of Ulsan | Date: 2016-12-07

Provided is a semiconductor-based ion-responsive urine sensor (IRUS) capable of detecting an analyte in urine by a non-invasive method. When a urine sensor according to an aspect is used, it is possible to diagnose a patient accurately in a comfortable condition and to use the urine sensor for point-of-care (POC) diagnosis.


Patent
InBody Co., University of Ulsan and Postech Academy Industry Foundation | Date: 2016-12-27

Disclosed is a method of monitoring consciousness, the method including sensing at least two brainwave signals, extracting respective phase signals from the sensed brainwave signals, calculating entropy based on a variety in a change in terms of a phase difference between the extracted phase signals, and assessing a state of consciousness based on the calculated entropy.


Patent
Seoul National University, University of Ulsan, Korea Institute of Science, Technology and Pharsogen | Date: 2016-11-29

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.


A method for detecting disease using a manometry includes obtaining pressure values from each of the plurality of pressure sensors during a pre-set time, obtaining a three-dimensional pressure distribution showing the changes in the pressure values according to location and time by using the time, the pressure values, and locations in which the pressure sensors are disposed within the arbitrary location section, and calculating the volume integral value of the interest location which is predetermined in accordance with the disease, in the three-dimensional pressure distribution.


Patent
University of Ulsan | Date: 2017-09-27

The present invention relates to a peptide for targeting gastric cancer, a composition for diagnosing radioresponsiveness-dependent gastric cancer using the peptide, and a drug delivery use of the peptide. A functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients. After establishing animal models similar to cancer microenvironments of actual patients and dividing them into an irradiated population and a non-irradiated population as a control group, targeting efficiency has been tested for respective peptides selected by screening peptides specifically binding to the respective populations. As such, the present invention can be finally utilized in the technical development of image diagnosis for predicting responsiveness to radiotherapy, and accordingly, in the development of customized targeted therapeutic agents.


Patent
University of Ulsan | Date: 2017-09-27

The present invention relates to a peptide for targeting colorectal cancer, a composition for diagnosing radioresponsiveness-dependent prognosis of colorectal cancer using the peptide, and a drug delivery use of the peptide. A functional peptide capable of targeting cancer has been discovered so as to implement personalized diagnosis and treatment for individual patients having cancer, in consideration of problems occurring during treatment in which treatment cases of respective patients differ due to different therapeutic responses resulting from genetic differences in the individual patients. After establishing animal models similar to cancer microenvironments of actual patients and dividing them into an irradiated population and a non-irradiated population as a control group, targeting efficiency has been tested for respective peptides selected by screening peptides specifically binding to the respective populations. As such, the present invention can be finally utilized in the technical development of image diagnosis for predicting responsiveness to radiotherapy, and accordingly, in the development of customized targeted therapeutic agents.


Lee D.H.,University of Ulsan
Pharmacology and Therapeutics | Year: 2017

The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) have changed the paradigm of cancer therapy from empirical cytotoxic chemotherapy to molecular-targeted cancer therapy. As a result, EGFR TKI therapy, including gefitinib, erlotinib and afatinib, has become the standard therapy for NSCLC patients with EGFR activating mutation as first-line therapy. However, most patients inevitably progress despite initial dramatic and rapid response to EGFR TKIs and therefore during the last decade, a lot of efforts have been made to identify and overcome various resistance mechanisms. Fortunately, T790M secondary mutation, the main resistance mechanism, can be overcome by newly developed third-generation EGFR TKIs, such as osimertinib, while most combination trials trying to overcome resistance mechanisms other than T790M mutation have failed so far. To make it worse, spatial and temporal tumor heterogeneity and clonal selection or evolution are also identified in EGFR mutant NSCLC tumors. Nevertheless, advance of comprehensive and more sensitive molecular diagnostics and monitoring technology, such as next-generation sequencing and dynamic monitoring technology using circulating biomarker and development of new cancer medicine with different mechanisms from EGFR TKIs, especially immune checkpoint inhibitors, might affect or change the treatment paradigm of EGFR mutant NSCLC in the near future. © 2017 Elsevier Inc.


BACKGROUND—: Calcification of the aortic valve leads to increased leaflet stiffness, and consequently to the development of calcific aortic valve disease (CAVD); however, the underlying molecular and cellular mechanisms of calcification remain unclear. Here, we identified that dipeptidyl peptidase-4 (DPP-4, also known as CD26) increases valvular calcification and promotes CAVD progression. METHODS—: We obtained the aortic valve tissues from humans and murine models (wild type and eNOS mice), and cultured the valvular interstitial cells (VICs) and valvular endothelial cells (VECs) from the cusps. We induced osteogenic differentiation in the primary cultured VICs and examined the effects of the DPP-4 inhibitor on the osteogenic changes in vitro and aortic valve calcification in eNOS mice. We also induced calcific aortic stenosis in male New Zealand rabbits (weight, 2.5–3.0 kg) via a cholesterol-enriched diet+vitamin D2 (25,000 IU, daily). Echocardiography was performed to assess the aortic valve area, and the maximal and mean trans-aortic pressure gradients at baseline and at 3-week intervals thereafter. After 12 weeks, we harvested the heart and evaluated the aortic valve tissue using immunohistochemistry. RESULTS—: We found that nitric oxide depletion in human VECs activates NF-κB in human VICs. Consequently, the NF-κB promotes DPP-4 expression, which then induces the osteogenic differentiation of VICs by limiting autocrine insulin-like growth factor-1 (IGF-1) signaling. The inhibition of DPP-4 enzymatic activity blocked the osteogenic changes in VICs in vitro and reduced the aortic valve calcification in vivo in a mouse model. Sitagliptin administration in a rabbit CAVD model led to significant improvements in the rate of change in aortic valve area, transaortic peak velocity, and maximal and mean pressure gradients over 12 weeks. Immunohistochemistry staining confirmed the therapeutic effect of Sitagliptin in terms of reducing the calcium deposits in the rabbit aortic valve cusps. In rabbits receiving Sitagliptin, the plasma IGF-1 levels were significantly increased, in line with DPP-4 inhibition. CONCLUSIONS—: DPP-4-dependent IGF-1 inhibition in VICs contributes to aortic valve calcification, suggesting that DPP-4 could serve as a potential therapeutic target to inhibit CAVD progression. © 2017 by the American College of Cardiology Foundation and the American Heart Association, Inc.


BACKGROUND—: We evaluated the prognosis of deferred and revascularized coronary stenoses after FFR measurement to assess its revascularization threshold in clinical practice. METHODS—: The IRIS-FFR registry prospectively enrolled 5846 patients with at least one coronary lesion with FFR measurement. Revascularization was deferred in 6468 lesions and performed in 2165 lesions after FFR assessment. The primary endpoint was major adverse cardiac events (MACE; cardiac death, myocardial infarction, and repeat revascularization) at a median follow-up of 1.9 years and analyzed on a per-lesion basis. A marginal Cox model accounted for correlated data in patients with multiple lesions, and a model to predict per-lesion outcomes was adjusted for confounding factors. RESULTS—: For deferred lesions, the risk of MACE demonstrated a significant, inverse relationship with FFR (adjusted hazard ratio [aHR], 1.06; 95% confidence interval [CI], 1.05-1.08; P < 0.001). However, this relationship was not observed in revascularized lesions (aHR, 1.00; 95% CI, 0.98-1.02; P = 0.70). For lesions with FFR ≥ 0.76, the risk of MACE was not significantly different between deferred and revascularized lesions. Conversely, in lesions with FFR ≤ 0.75, the risk of MACE was significantly lower in revascularized lesions than in deferred lesions (for FFR 0.71-0.75, aHR, 0.47; 95% CI, 0.24-0.89; P = 0.021, and for FFR ≤ 0.70, aHR 0.47; 95% CI, 0.26-0.84; P = 0.012). CONCLUSIONS—: This large, prospective registry showed that the FFR value was linearly associated with the risk of cardiac events in deferred lesions. In addition, revascularization for coronary artery stenosis with a low FFR (≤ 0.75) was associated with better outcomes than the deferral, while for a stenosis with a high FFR (≥ 0.76), medical treatment would be a reasonable and safe treatment strategy. CLINICAL TRIAL REGISTRATION—: clinicaltrials.gov Identifier: NCT01366404. © 2017 by the American College of Cardiology Foundation and the American Heart Association, Inc.

Loading University of Ulsan collaborators
Loading University of Ulsan collaborators